Targeted synthetic DMARDs, like JAK inhibitors, have shown efficacy in controlling RA activity although more recent data seem to suggest a higher risk of cancer and CV events compared to TNF inhibitors. This evidence concerns the gene TNF and rheumatoid arthritis.